Stimulant Abuse: Pharmacology, Cocaine, Methamphetamine, Treatment, Attempts at Pharmacotherapy

Primary Care - Clinics in Office Practice

Volumn 38, Issue 1, 2011, Pages 41-58

  Ciccarone, Daniel ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amphetamine; Cocaine; Methamphetamine; Stimulants

Indexed keywords

AMPHETAMINE; AMPHETAMINE DERIVATIVE; CAFFEINE; COCAINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DRUGS USED IN THE TREATMENT OF ADDICTION; FENFLURAMINE; ILLICIT DRUG; METHAMPHETAMINE; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT; NORADRENALIN; PHENTERMINE; PHENYLPROPANOLAMINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL;

ATTENTION DEFICIT DISORDER; BEHAVIOR THEORY; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; COCAINE DEPENDENCE; COGNITIVE THERAPY; DRUG DEPENDENCE; DRUG LEGISLATION; DRUG MISUSE; DRUG OVERDOSE; DRUG TOLERANCE; DRUG TRAFFIC; ENDOCRINE DISEASE; ERECTILE DYSFUNCTION; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; HEAD AND NECK DISEASE; HEART VALVE REGURGITATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOLOGY; INTOXICATION; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; METHAMPHETAMINE DEPENDENCE; MORTALITY; MUSCULOSKELETAL DISEASE; NARCOLEPSY; NEUROMODULATION; PHYSICAL CHEMISTRY; PRESCRIPTION; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; PULMONARY HYPERTENSION; REVIEW; SEXUAL DYSFUNCTION; SOCIAL BEHAVIOR; WITHDRAWAL SYNDROME;

AMPHETAMINE; AMPHETAMINE-RELATED DISORDERS; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; COCAINE-RELATED DISORDERS; DOPAMINE UPTAKE INHIBITORS; HIV INFECTIONS; HUMANS; METHAMPHETAMINE; PRIMARY HEALTH CARE; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 79951973019     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2010.11.004     Document Type: Review

References (146)

1. Thoumi F.E. Illegal drugs, economy, and society in the Andes 2003, Woodrow Wilson Center Press, Washington, DC.
2. Spillane J.F. Cocaine: from medical marvel to modern menace in the United States, 1884-1920 2000, Johns Hopkins University Press, Baltimore (MD).
3. Musto D.F. The American disease: origins of narcotic control 1999, Oxford University Press, New York. 3rd edition.
4. Crack in America: demon drugs and social justice 1997, 18-51. University of California Press, Berkeley (CA). C. Reinarman, H.G. Levine (Eds.).
5. Rasmussen N. Making the first anti-depressant: amphetamine in American medicine, 1929-1950. J Hist Med Allied Sci 2006, 61(3):288-323.
6. Goode E. Drugs in American society 2005, McGraw-Hill, New York. 6th edition.
7. Hunt D, Kuck S, Truitt L. Methamphetamine use: lessons learned, final report to the National Institute of Justice 2006, February 2006 (NCJ 209730). Available at: Accessed March 27, 2010. http://www.ncjrs.gov/pdffiles1/nij/grants/209730.pdf.
8. Wikipedia contributors. Benzedrine. Wikipedia, The Free Encyclopedia. Available at: Accessed December 20, 2010. http://en.wikipedia.org/wiki/Benzedrine.
9. Wikipedia contributors. Amphetamine. Wikipedia, The Free Encyclopedia. Available at: Accessed December 20, 2010. http://en.wikipedia.org/wiki/Amphetamine.
10. Substance Abuse and Mental Health Services Administration Results from the 2008 National Survey on Drug Use and Health: National findings 2009, NSDUH Series H-36, HHS Publication No. SMA 09-4434, Office of Applied Studies, Rockville (MD).
11. Maxwell J.C., Rutkowski B.A. The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992-2007. Drug Alcohol Rev 2008, 27(3):229-235.
12. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network, 2006: National estimates of drug-related emergency department visits. DAWN Series D-30, DHHS Publication No. (SMA) 08-4339 2008, Department of Health and Human Services, Rockville (MD).
13. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network, 2007: area profiles of drug-related mortality. HHS Publication No. SMA 09-4407, DAWN Series D-31 2009, Department of Health and Human Services, Rockville (MD).
14. Nicosia N., Pacula R.L., Kilmer B., et al. The economic cost of methamphetamine use in the United States, 2005 2009, RAND Drug Policy Research Center, Santa Monica (CA).
15. United Nations Office on Drugs and Crime. 2009 World Drug Report. Vienna, 2009.
16. Hatsukami D.K., Fischman M.W. Crack cocaine and cocaine hydrochloride. Are the differences myth or reality?. JAMA 1996, 276(19):1580-1588.
17. Urban Dictionary contributors Cocaine Available at:, Accessed December 20, 2010. http://www.urbandictionary.com/define.php?term=cocaine.
18. Volkow N.D., Wang G.J., Fischman M.W., et al. Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. Life Sci 2000, 67(12):1507-1515.
19. US Drug Enforcement Administration "DEA history book, 1876-1990" (drug usage & enforcement), US Department of Justice USDoJ.gov webpage: Available at:, Accessed March 31, 2010. http://www.justice.gov/dea/pubs/history/1985%131990.html.
20. US Department of Justice, National Drug Intelligence Center. National drug threat assessment 2009 2008, National Drug Intelligence Center, Washington, DC.
21. Shesser R., Jotte R., Olshaker J. The contribution of impurities to the acute morbidity of illegal drug use. Am J Emerg Med 1991, 9:336-342.
22. Kinzie E. Levamisole found in patients using cocaine. Ann Emerg Med 2009, 53(4):546-547.
23. Knowles L., Buxton J.A., Skuridina N., et al. Levamisole tainted cocaine causing severe neutropenia in Alberta and British Columbia. Harm Reduct J 2009, 6:30.
24. US Drug Enforcement Administration Stats and facts Available at:, Accessed April 2, 2010. http://www.justice.gov/dea/statistics.html.
25. US Department of Justice, National Drug Intelligence Center. National methamphetamine threat assessment 2007 2006, National Drug Intelligence Center, Washington, DC.
26. Ellenhorn M.J., Schonwald S., Ordog G., et al. Ellenhorn's medical toxicology: diagnosis and treatment of human poisoning 1997, Williams and Wilkins, Baltimore (MD). 2nd edition.
27. Cho A.K., Melega W.P. Patterns of methamphetamine abuse and their consequences. J Addict Dis 2002, 21(1):21-34.
28. Schifano F., Corkery J.M., Cuffolo G. Smokable (" ice" , "crystal meth" ) and non smokable amphetamine-type stimulants: clinical pharmacological and epidemiological issues, with special reference to the UK. Ann Ist Super Sanità 2007, 43(1):110-115.
29. Masand P.S., Tesar G.E. Use of stimulants in the medically ill. Psychiatr Clin North Am 1996, 19(3):515-547.
30. Warner M. A jolt of caffeine, by the can. New York Times November 23, 2005.
31. McCabe S.E., Teter C.J., Boyd C.J. Medical use, illicit use and diversion of prescription stimulant medication. J Psychoactive Drugs 2006, 38(1):43-56.
32. Volkow N.D., Swanson J.M. Does childhood treatment of ADHD with stimulant medication affect substance abuse in adulthood?. Am J Psychiatry 2008, 165(5):553-555.
33. Sachdev M., Miller W.C., Ryan T., et al. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J 2002, 144(6):1065-1073.
34. Kernan W.N., Viscoli C.M., Brass L.M., et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000, 343(25):1826-1832.
35. Fleckenstein A.E., Volz T.J., Riddle E.L., et al. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 2007, 47:681-698.
36. Howell L.L., Kimmel H.L. Monoamine transporters and psychostimulant addiction. Biochem Pharmacol 2008, 75(1):196-217.
37. Volkow N.D., Fowler J.S., Wang G.J., et al. Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 2009, 56(Suppl 1):3-8.
38. Wee S., Carroll F.I., Woolverton W.L. A reduced rate of in vivo dopamine transporter binding is associated with lower relative reinforcing efficacy of stimulants. Neuropsychopharmacology 2006, 31(2):351-362.
39. Chen R., Tilley M.R., Wei H., et al. Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. Proc Natl Acad Sci U S A 2006, 103(24):9333-9338.
40. Caine S.B., Thomsen M., Gabriel K.I., et al. Lack of self-administration of cocaine in dopamine D1 receptor knock-out mice. J Neurosci 2007, 27(48):13140-13150.
41. Kimmel H.L., O'Connor J.A., Carroll F.I., et al. Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys. Pharmacol Biochem Behav 2007, 86(1):45-54.
42. Kuhar M.J., Ritz M.C., Boja J.W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 1991, 14(7):299-302.
43. Filip M., Frankowska M., Zaniewska M., et al. The serotonergic system and its role in cocaine addiction. Pharmacol Rep 2005, 57(6):685-700.
44. Rothman R.B., Baumann M.H., Dersch C.M., et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001, 39(1):32-41.
45. Gass J.T., Olive M.F. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 2008, 75(1):218-265.
46. Williams M.J., Adinoff B. The role of acetylcholine in cocaine addiction. Neuropsychopharmacology 2008, 33(8):1779-1797.
47. Romanelli F., Smith K.M. Clinical effects and management of methamphetamine abuse. Pharmacotherapy 2006, 26(8):1148-1156.
48. Gorelick D.A. The pharmacology of cocaine, amphetamines, and other stimulants. Principles of addiction medicine 2009, 142. Wolters Kluwer, Lippincott Williams and Wilkins, Philadelphia (PA). 4th edition. R.K. Ries, D.A. Fiellin, S.C. Miller (Eds.).
49. Hando J., Topp L., Hall W. Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug Alcohol Depend 1997, 46(1-2):105-113.
50. Peck J.A., Shoptaw S., Rotheram-Fuller E., et al. HIV-associated medical, behavioral, and psychiatric characteristics of treatment-seeking, methamphetamine-dependent men who have sex with men. J Addict Dis 2005, 24(3):115-132.
51. O'Connor A.D., Rusyniak D.E., Bruno A. Cerebrovascular and cardiovascular complications of alcohol and sympathomimetic drug abuse. Med Clin North Am 2005, 89(6):1343-1358.
52. Gay G.R. Clinical management of acute and chronic cocaine poisoning. Ann Emerg Med 1982, 11(10):562-572.
53. Colfax G., Shoptaw S. The methamphetamine epidemic: implications for HIV prevention and treatment. Curr HIV/AIDS Rep 2005, 2(4):194-199.
54. Myers M.G., Rohsenow D.J., Monti P.M., et al. Patterns of cocaine use among individuals in substance abuse treatment. Am J Drug Alcohol Abuse 1995, 21(2):223-231.
55. O'Brien C.P., Gardner E.L. Critical assessment of how to study addiction and its treatment: human and non-human animal models. Pharmacol Ther 2005, 108(1):18-58.
56. Kalivas P.W., Pierce R.C., Cornish J., et al. A role for sensitization in craving and relapse in cocaine addiction. J Psychopharmacol 1998, 12(1):49-53.
57. Robinson T.E., Berridge K.C. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 2000, 95(Suppl 2):S91-S117.
58. Bonate P.L., Swann A., Silverman P.B. Context-dependent cross-sensitization between cocaine and amphetamine. Life Sci 1997, 60(1):PL1-PL7.
59. Mahoney J.J., Kalechstein A.D., De La Garza R., et al. Presence and persistence of psychotic symptoms in cocaine-versus methamphetamine-dependent participants. Am J Addict 2008, 17(2):83-98.
60. Fasano A., Barra A., Nicosia P., et al. Cocaine addiction: from habits to stereotypical-repetitive behaviors and punding. Drug Alcohol Depend 2008, 96(1-2):178-182.
61. Hall W., Hando J., Darke S., et al. Psychological morbidity and route of administration among amphetamine users in Sydney, Australia. Addiction 1996, 91(1):81-87.
62. Williamson S., Gossop M., Powis B., et al. Adverse effects of stimulant drugs in a community sample of drug users. Drug Alcohol Depend 1997, 44(2-3):87-94.
63. Flaum M., Schultz S.K. When does amphetamine-induced psychosis become schizophrenia?. Am J Psychiatry 1996, 153(6):812-815.
64. Yui K., Ishiguro T., Goto K., et al. Factors affecting the development of spontaneous recurrence of methamphetamine psychosis. Acta Psychiatr Scand 1998, 97(3):220-227.
65. Mendelson J.H., Sholar M., Mello N.K., et al. Cocaine tolerance: behavioral, cardiovascular, and neuroendocrine function in men. Neuropsychopharmacology 1998, 18(4):263-271.
66. Lim K.O., Wozniak J.R., Mueller B.A., et al. Brain macrostructural and microstructural abnormalities in cocaine dependence. Drug Alcohol Depend 2008, 92(1-3):164-172.
67. Yucel M., Lubman D.I., Solowij N., et al. Understanding drug addiction: a neuropsychological perspective. Aust N Z J Psychiatry 2007, 41(12):957-968.
68. Coffey S.F., Dansky B.S., Carrigan M.H., et al. Acute and protracted cocaine abstinence in an outpatient population: a prospective study of mood, sleep and withdrawal symptoms. Drug Alcohol Depend 2000, 59(3):277-286.
69. Lago J.A., Kosten T.R. Stimulant withdrawal. Addiction 1994, 89(11):1477-1481.
70. Anthony J.C., Warner L.A., Kessler R.C. Comparitive epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 1994, 2:244-268.
71. Woody G.E., Cottler L.B., Cacciola J. Severity of dependence: data from the DSM-IV field trials. Addiction 1993, 88(11):1573-1579.
72. Gossop M., Griffiths P., Powis B., et al. Cocaine: patterns of use, route of administration, and severity of dependence. Br J Psychiatry 1994, 164(5):660-664.
73. Gorelick D.A. The rate hypothesis and agonist substitution approaches to cocaine abuse treatment. Adv Pharmacol 1998, 42:995-997.
74. Association A.P. Diagnostic and statistical manual of mental disorders 2000, Text Revision, American Psychiatric Association, Washington, DC. 4th edition.
75. Agrawal A., Lynskey M.T. Are there genetic influences on addiction: evidence from family, adoption and twin studies. Addiction 2008, 103(7):1069-1081.
76. Boghdadi M.S., Henning R.J. Cocaine: pathophysiology and clinical toxicology. Heart Lung 1997, 26(6):466-483. [quiz: 484-5].
77. Qureshi A.I., Suri M.F., Guterman L.R., et al. Cocaine use and the likelihood of nonfatal myocardial infarction and stroke: data from the Third National Health and Nutrition Examination Survey. Circulation 2001, 103(4):502-506.
78. Gitman M.D., Singhal P.C. Cocaine-induced renal disease. Expert Opin Drug Saf 2004, 3(5):441-448.
79. Glauser J., Queen J.R. An overview of non-cardiac cocaine toxicity. J Emerg Med 2007, 32(2):181-186.
80. Doctora J.S., Williams C.W., Bennett C.R., et al. Rhabdomyolysis in the acutely cocaine-intoxicated patient sustaining maxillofacial trauma: report of a case and review of the literature. J Oral Maxillofac Surg 2003, 61(8):964-967.
81. Goodger N.M., Wang J., Pogrel M.A. Palatal and nasal necrosis resulting from cocaine misuse. Br Dent J 2005, 198(6):333-334.
82. Kuczkowski K.M. The effects of drug abuse on pregnancy. Curr Opin Obstet Gynecol 2007, 19(6):578-585.
83. Phupong V., Darojn D. Amphetamine abuse in pregnancy: the impact on obstetric outcome. Arch Gynecol Obstet 2007, 276(2):167-170.
84. Williams J.H., Ross L. Consequences of prenatal toxin exposure for mental health in children and adolescents: a systematic review. Eur Child Adolesc Psychiatry 2007, 16(4):243-253.
85. Neiman J., Haapaniemi H.M., Hillbom M. Neurological complications of drug abuse: pathophysiological mechanisms. Eur J Neurol 2000, 7(6):595-606.
86. Warner E.A. Cocaine abuse. Ann Intern Med 1993, 119(3):226-235.
87. Harris D., Batki S.L. Stimulant psychosis: symptom profile and acute clinical course. Am J Addict 2000, 9(1):28-37.
88. Featherstone R.E., Kapur S., Fletcher P.J. The amphetamine-induced sensitized state as a model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31(8):1556-1571.
89. Buffenstein A., Heaster J., Ko P. Chronic psychotic illness from methamphetamine. Am J Psychiatry 1999, 156(4):662.
90. Mello N.K., Mendelson J.H. Cocaine's effects on neuroendocrine systems: clinical and preclinical studies. Pharmacol Biochem Behav 1997, 57(3):571-599.
91. Carey J.C. Pharmacological effects on sexual function. Obstet Gynecol Clin North Am 2006, 33(4):599-620.
92. Afonso L., Mohammad T., Thatai D. Crack whips the heart: a review of the cardiovascular toxicity of cocaine. Am J Cardiol 2007, 100(6):1040-1043.
93. Lange R.A., Hillis L.D. Cardiovascular complications of cocaine use. N Engl J Med 2001, 345(5):351-358.
94. Yeo K.K., Wijetunga M., Ito H., et al. The association of methamphetamine use and cardiomyopathy in young patients. Am J Med 2007, 120(2):165-171.
95. Tashkin D.P. Airway effects of marijuana, cocaine, and other inhaled illicit agents. Curr Opin Pulm Med 2001, 7(2):43-61.
96. Wolff A.J., O'Donnell A.E. Pulmonary effects of illicit drug use. Clin Chest Med 2004, 25(1):203-216.
97. Shoptaw S. Methamphetamine use in urban gay and bisexual populations. Top HIV Med 2006, 14(2):84-87.
98. Des Jarlais D.C., Friedman S.R. HIV infection among intravenous drug users: epidemiology and risk reduction. AIDS 1987, 1(2):67-76.
99. Chaisson R.E., Bacchetti P., Osmond D., et al. Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA 1989, 261(4):561-565.
100. Hahn J.A., Page-Shafer K., Lum P.J., et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis 2002, 186(11):1558-1564.
101. Booth R.E., Watters J.K., Chitwood D.D. HIV risk-related sex behaviors among injection drug users, crack smokers, and injection drug users who smoke crack. Am J Public Health 1993, 83(8):1144-1148.
102. Edlin B.R., Irwin K.L., Faruque S., et al. Intersecting epidemics-crack cocaine use and HIV infection among inner-city young adults. Multicenter Crack Cocaine and HIV Infection Study Team. N Engl J Med 1994, 331(21):1422-1427.
103. Fisher D.G., Reynolds G.L., Napper L.E. Use of crystal methamphetamine, Viagra, and sexual behavior. Curr Opin Infect Dis 2010, 23(1):53-56.
104. Stall R., Paul J.P., Greenwood G., et al. Alcohol use, drug use and alcohol-related problems among men who have sex with men: the Urban Men's Health Study. Addiction 2001, 96(11):1589-1601.
105. Colfax G., Coates T.J., Husnik M.J., et al. Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men. J Urban Health 2005, 82(1 Suppl 1):i62-i70.
106. Halkitis P.N., Mukherjee P.P., Palamar J.J. Longitudinal modeling of methamphetamine use and sexual risk behaviors in gay and bisexual men. AIDS Behav 2009, 13(4):783-791.
107. Thiede H., Jenkins R.A., Carey J.W., et al. Determinants of recent HIV infection among Seattle-area men who have sex with men. Am J Public Health 2009, 99(Suppl 1):S157-S164.
108. Semple S.J., Strathdee S.A., Zians J., et al. Sexual risk behavior associated with co-administration of methamphetamine and other drugs in a sample of HIV-positive men who have sex with men. Am J Addict 2009, 18(1):65-72.
109. Prestage G., Jin F., Kippax S., et al. Use of illicit drugs and erectile dysfunction medications and subsequent HIV infection among gay men in Sydney, Australia. J Sex Med 2009, 6(8):2311-2320.
110. Sanchez T.H., Gallagher K.M. Factors associated with recent sildenafil (Viagra) use among men who have sex with men in the United States. J Acquir Immune Defic Syndr 2006, 42(1):95-100.
111. Ostrow D.G., Plankey M.W., Cox C., et al. Specific sex drug combinations contribute to the majority of recent HIV seroconversions among MSM in the MACS. J Acquir Immune Defic Syndr 2009, 51(3):349-355.
112. Screening and Behavioral Counseling Interventions in Primary Care to Reduce Alcohol Misuse, Topic Page. April 2004. U.S. Preventive Services Task Force. Accessed November 23, 2010. http://www.uspreventiveservicestaskforce.org/uspstf/uspsdrin.htm.
113. Screening for Illicit Drug Use, Topic Page. January 2008. U.S. Preventive Services Task Force. Available at: Accessed December 17, 2010. http://www.uspreventiveservicestaskforce.org/uspstf/uspsdrug.htm.
114. Kulig J.W. Tobacco, alcohol, and other drugs: the role of the pediatrician in prevention, identification, and management of substance abuse. Pediatrics 2005, 115(3):816-821.
115. Guidelines for women's health care 2002, American College of Obstetricians and Gynecologists, Washington, DC. 2nd edition.
116. Center for Substance Abuse Treatment A guide to substance abuse services for primary care clinicians. Treatment Improvement Protocol (TIP) Series, Number 24. DHHS Pub. No. (SMA) 97-3139 1997, US Government Printing Office, Washington, DC.
117. Smith P.C., Schmidt S.M., Allensworth-Davies D., et al. A single-question screening test for drug use in primary care. Arch Intern Med 2010, 170(13):1155-1160.
118. Center for Substance Abuse Treatment Brief interventions and brief therapies for substance abuse. Treatment Improvement Protocol (TIP) Series, Number 34. DHHS Pub. No. (SMA) 99-3353 1999, US Government Printing Office, Washington, DC.
119. Bertholet N., Daeppen J.B., Wietlisbach V., et al. Reduction of alcohol consumption by brief alcohol intervention in primary care: systematic review and meta-analysis. Arch Intern Med 2005, 165(9):986-995.
120. Kaner E.F., Beyer F., Dickinson H.O., et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev 2007, 2. CD004148.
121. Whitlock E.P., Polen M.R., Green C.A., et al. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004, 140(7):557-568.
122. Madras B.K., Compton W.M., Avula D., et al. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alcohol Depend 2009, 99(1-3):280-295.
123. Bernstein J., Bernstein E., Tassiopoulos K., et al. Brief motivational intervention at a clinic visit reduces cocaine and heroin use. Drug Alcohol Depend 2005, 77(1):49-59.
124. Baker A., Lee N.K., Claire M., et al. Brief cognitive behavioural interventions for regular amphetamine users: a step in the right direction. Addiction 2005, 100(3):367-378.
125. Vocci F.J., Montoya I.D. Psychological treatments for stimulant misuse, comparing and contrasting those for amphetamine dependence and those for cocaine dependence. Curr Opin Psychiatry 2009, 22(3):263-268.
126. Dutra L., Stathopoulou G., Basden S.L., et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008, 165(2):179-187.
127. Carroll K.M., Nich C., Ball S.A., et al. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998, 93(5):713-727.
128. Maude-Griffin P.M., Hohenstein J.M., Humfleet G.L., et al. Superior efficacy of cognitive-behavioral therapy for urban crack cocaine abusers: main and matching effects. J Consult Clin Psychol 1998, 66(5):832-837.
129. Monti P.M., Rohsenow D.J., Michalec E., et al. Brief coping skills treatment for cocaine abuse: substance use outcomes at three months. Addiction 1997, 92(12):1717-1728.
130. Carroll K.M., Rounsaville B.J., Gawin F.H. A comparative trial of psychotherapies for ambulatory cocaine abusers: relapse prevention and interpersonal psychotherapy. Am J Drug Alcohol Abuse 1991, 17(3):229-247.
131. Lee N.K., Rawson R.A. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev 2008, 27(3):309-317.
132. Higgins S.T., Tidey J.W., Rogers R.E. Contingency management and the community reinforcement approach. Principles of addiction medicine 2009, 787, 788. Wolters Kluwer, Lippincott Williams and Wilkins, Philadelphia (PA). 4th edition. R.K. Ries, D.A. Fiellin, S.C. Miller (Eds.).
133. Griffith J.D., Rowan-Szal G.A., Roark R.R., et al. Contingency management in outpatient methadone treatment: a meta-analysis. Drug Alcohol Depend 2000, 58(1-2):55-66.
134. Lussier J.P., Heil S.H., Mongeon J.A., et al. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction 2006, 101(2):192-203.
135. Prendergast M.L., Podus D., Chang E., et al. The effectiveness of drug abuse treatment: a meta-analysis of comparison group studies. Drug Alcohol Depend 2002, 67(1):53-72.
136. Epstein D.H., Hawkins W.E., Covi L., et al. Cognitive-behavioral therapy plus contingency management for cocaine use: findings during treatment and across 12-month follow-up. Psychol Addict Behav 2003, 17(1):73-82.
137. Higgins S.T., Wong C.J., Badger G.J., et al. Contingent reinforcement increases cocaine abstinence during outpatient treatment and 1 year of follow-up. J Consult Clin Psychol 2000, 68(1):64-72.
138. Petry N.M., Alessi S.M., Hanson T. Contingency management improves abstinence and quality of life in cocaine abusers. J Consult Clin Psychol 2007, 75(2):307-315.
139. Secades-Villa R., Garcia-Rodriguez O., Higgins S.T., et al. Community reinforcement approach plus vouchers for cocaine dependence in a community setting in Spain: six-month outcomes. J Subst Abuse Treat 2008, 34(2):202-207.
140. Rawson R.A., McCann M.J., Flammino F., et al. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction 2006, 101(2):267-274.
141. Roll J.M., Petry N.M., Stitzer M.L., et al. Contingency management for the treatment of methamphetamine use disorders. Am J Psychiatry 2006, 163(11):1993-1999.
142. Shoptaw S., Reback C.J., Peck J.A., et al. Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. Drug Alcohol Depend 2005, 78(2):125-134.
143. Lima M.S., Reisser A.A., Soares B.G., et al. Antidepressants for cocaine dependence. Cochrane Database Syst Rev 2003, 2. CD002950.
144. Elkashef A., Holmes T.H., Bloch D.A., et al. Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependence. Addiction 2005, 100(Suppl 1):91-101.
145. Moeller F.G., Schmitz J.M., Steinberg J.L., et al. Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. Am J Drug Alcohol Abuse 2007, 33(3):367-378.
146. Poling J., Oliveto A., Petry N., et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry 2006, 63(2):219-228.